[{"orgOrder":0,"company":"Danisco","sponsor":"University of Turku | 4Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Danisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Danisco \/ University of Turku | 4Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Danisco \/ University of Turku | 4Pharma"},{"orgOrder":0,"company":"Veterans Medical Research Foundation","sponsor":"National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Veterans Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Veterans Medical Research Foundation \/ National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego","highestDevelopmentStatusID":"6","companyTruncated":"Veterans Medical Research Foundation \/ National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego"},{"orgOrder":0,"company":"Veterans Medical Research Foundation","sponsor":"San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Veterans Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Veterans Medical Research Foundation \/ San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Veterans Medical Research Foundation \/ San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"The Hershey Company","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ The Hershey Company","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ The Hershey Company"},{"orgOrder":0,"company":"Epirium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epirium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Undisclosed"},{"orgOrder":0,"company":"Epirium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epirium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Undisclosed"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Epirium","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Collaboration","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Piramal Pharma Solutions \/ Epirium","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Pharma Solutions \/ Epirium"},{"orgOrder":0,"company":"Epirium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epirium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Undisclosed"},{"orgOrder":0,"company":"Ralitza Gavrilova","sponsor":"Cardero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ralitza Gavrilova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ralitza Gavrilova \/ Cardero Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Ralitza Gavrilova \/ Cardero Therapeutics"},{"orgOrder":0,"company":"Craig McDonald","sponsor":"Cardero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Craig McDonald","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Craig McDonald \/ Cardero Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Craig McDonald \/ Cardero Therapeutics"},{"orgOrder":0,"company":"Craig McDonald","sponsor":"Cardero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Craig McDonald","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Craig McDonald \/ Cardero Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Craig McDonald \/ Cardero Therapeutics"},{"orgOrder":0,"company":"Craig McDonald","sponsor":"Cardero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Craig McDonald","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Craig McDonald \/ Cardero Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Craig McDonald \/ Cardero Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals for Epicatechin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Epirium has advanced its first clinical candidate EPM-01 (Epicatechin) in Becker muscular dystrophy and plans to follow with drug development targeting other disorders associated with mitochondrial dysfunction and tissue degeneration.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Undisclosed

                          August 27, 2020

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Epirium

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The Phase 1 open-label, dose-escalation study is evaluating the safety, preliminary clinical efficacy and potential biomarkers of three doses of EPM-01 in participants with Becker or Becker-like muscular dystrophy.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          August 12, 2020

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          May 13, 2020

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The company's prior studies have shown that EB 002 can stimulate mitochondrial biogenesis, contributing to the restoration of tissue bioenergetics, thus upregulating key protein production.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          April 14, 2020

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Craig McDonald

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Craig McDonald

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          August 02, 2017

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Cardero Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Craig McDonald

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Craig McDonald

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          November 16, 2016

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Cardero Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Ralitza Gavrilova

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Ralitza Gavrilova

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Friedreich Ataxia.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          January 21, 2016

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Cardero Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Veterans Medical Research Foundation

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Veterans Medical Research Foundation

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          January 14, 2016

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : San Diego Veterans Healthcare System | National Center for Complementary and Integrative Health | University of California, San Diego | National Institutes of Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Veterans Medical Research Foundation

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Veterans Medical Research Foundation

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          January 01, 2015

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : National Institutes of Health | National Center for Complementary and Integrative Health | San Diego Veterans Healthcare System | University of California, San Diego

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Craig McDonald

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Craig McDonald

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Epicatechin is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Muscular Dystrophy, Duchenne.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          May 17, 2013

                          Lead Product(s) : Epicatechin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Cardero Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank